The effects of allergic diseases such as allergic rhinitis, allergic rhinoconjunctivitis, and urticaria are now widely observed. Radiant Pharmaceuticals Limited has launched Fixtat™ second-generation antihistamine from 17th September 2023 to eliminate all these allergy-related issues.
Fixtat™ is a highly effective and safe medication that follows the morning conditions of the ARIA guidelines and is the only antihistamine recommended by the BNF indicated in allergic rhinoconjunctivitis. Fixtat™ is also safe for renal, hepatic, and cardiac patients. Fixtat™ uses API of USDMF grade which ensures the purity, efficacy, and safety of FixtatTM.
